Beranda › Masalah Mata Akibat Diabetes › California
Uji klinis Masalah Mata Akibat Diabetes di California
6 studi untuk Masalah Mata Akibat Diabetes mencari peserta di lokasi di California.
Kota di California
Teks studi resmi (Bahasa Inggris)
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)
- Global Research Management ( Site 0066), Glendale
- Retinal Consultants Medical Group ( Site 0013), Sacramento
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT07705555Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema
- California Retina Consultants - Bakersfield /ID# 282990, Bakersfield
- Retina-Vitreous Associates Medical Group - Beverly Hills /ID# 282995, Beverly Hills
- The Retina Partners /ID# 274741, Encino
- dan 6 lainnya
Menerima pesertaFase 2/3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT07592273A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7663498 Following Intravitreal Administration in Participants With Diabetic Retinopathy
- Global Research Management, Glendale
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT07588100Village-Integrated Eye Worker Trial II
- University of California, San Francisco, San Francisco
Menerima pesertaSukarelawan sehat diterima
Usia 60 ke atas · Semua jenis kelamin · Diperbarui 9 Jun 2026 · NCT03752840Strategies for Improving Linkage-to-Care After Eye Disease Screening
- University of California, San Francisco, San Francisco
Menerima peserta
Usia 60 ke atas · Semua jenis kelamin · Diperbarui 29 Apr 2026 · NCT06943599High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy
- Retina Consultants of Orange County, Fullerton
Menerima pesertaFase 4
Usia 21 ke atas · Semua jenis kelamin · Diperbarui 10 Jul 2025 · NCT06662994Dari ClinicalTrials.gov, data diambil 4 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.